Symptomatic therapy in multiple sclerosis: Big pharma should do more

登录注册会员服务联系我们

Symptomatic therapy in multiple sclerosis: Big pharma should do more – NO

Published:2015-06-17 Issue:8 Volume:21 Page:978-979
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Hughes Stella E¹,Gray Orla M²

Affiliation:

1. Royal Victoria Hospital, Belfast HSC Trust, UK

2. Ulster Hospital Dundonald, South Eastern HSC Trust, UK

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458515587930

Reference5 articles.

1. Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

2. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial

3. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

4. Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of an iron-responsive subtype in two children diagnosed with relapsing-remitting multiple sclerosis using whole exome sequencing;Molecular Genetics and Metabolism Reports;2019-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP